Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial

Lancet
Francisco Fernández-AvilésGRACIA (Grupo de Análisis de la Cardiopatía Isquémica Aguda) Group

Abstract

In patients with ST-segment elevated myocardial infarction (STEMI), early post-thrombolysis routine angioplasty has been discouraged because of its association with high incidence of events. The GRACIA-1 trial was designed to reassess the benefits of an early post-thrombolysis interventional approach in the era of stents and new antiplatelet agents. 500 patients with thrombolysed STEMI (with recombinant tissue plasminogen activator) were randomly assigned to angiography and intervention if indicated within 24 h of thrombolysis, or to an ischaemia-guided conservative approach. The primary endpoint was the combined rate of death, reinfarction, or revascularisation at 12 months. Analysis was by intention to treat. Invasive treatment included stenting of the culprit artery in 80% (199 of 248) patients, bypass surgery in six (2%), non-culprit artery stenting in three, and no intervention in 40 (16%). Predischarge revascularisation was needed in 51 of 252 patients in the conservative group. By comparison with patients receiving conservative treatment, by 1 year, patients in the invasive group had lower frequency of primary endpoint (23 [9%] vs 51 [21%], risk ratio 0.44 [95% CI 0.28-0.70], p=0.0008), and they tended to have reduced ra...Continue Reading

References

Mar 15, 1996·Journal of the American College of Cardiology·F W VerheugtM J Van Eenige
Aug 2, 2002·The New England Journal of Medicine·Howard C Herrmann

❮ Previous
Next ❯

Citations

Nov 5, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Oliver KoethUNKNOWN Maximal Individual Therapy in Acute Myocardial Infarction Plus (MITRA Plus) Study Group
Mar 17, 2010·Wiener medizinische Wochenschrift·Alois SuessenbacherHannes F Alber
Apr 10, 2012·Journal of Thrombosis and Thrombolysis·Harold L Dauerman, Burton E Sobel
Nov 4, 2008·Internal and Emergency Medicine·Giovanni MelandriAngelo Branzi
Oct 9, 2009·The New England Journal of Medicine·Bradley R Wilsmore, Andrea D Wilsmore
Jun 26, 2009·The New England Journal of Medicine·Freek W A Verheugt
Jun 26, 2009·The New England Journal of Medicine·Warren J CantorUNKNOWN TRANSFER-AMI Trial Investigators
Aug 31, 2010·European Heart Journal·UNKNOWN Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardDavid Taggart
Dec 25, 2010·European Heart Journal·Pedro L Sánchez, Francisco Fernández-Avilés
Apr 16, 2005·BMJ : British Medical Journal·Jonathan N Townend, Sagar N Doshi
May 28, 2005·BMJ : British Medical Journal·Michael P PittNadia El Gaylani
Jun 7, 2006·Postgraduate Medical Journal·D Gray
Dec 7, 2007·Postgraduate Medical Journal·J B Jones, A Docherty
Oct 13, 2006·BMC Medicine·Peter Bogaty, James M Brophy
Jun 24, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Tomonori ItohUNKNOWN IMPORTANT investigators
Dec 7, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Warren J CantorLaurie J Morrison
Mar 14, 2007·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Danijela Dordević RadojkovićDusan Milenković
Dec 31, 2008·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Gerald S WernerUNKNOWN EuroCTO Club
Dec 30, 2008·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Gabriele GiulianiMassimo Margheri
Sep 24, 2009·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·S H SchirmerF Mahfoud
Jul 20, 2014·Revista Española De Cardiología·Nicolas DanchinEtienne Puymirat
Sep 18, 2013·Nature Reviews. Cardiology·Javaid IqbalDavid P Taggart
Oct 25, 2008·European Heart Journal·Nicolas DanchinDidier Blanchard
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Jul 1, 2005·Current Cardiology Reports·Derek P ChewHarvey D White
Jul 3, 2007·Current Cardiology Reports·Saumil R ShahC Michael Gibson
Aug 22, 2008·Current Cardiology Reports·David M Larson, Timothy D Henry
Aug 1, 2008·Der Internist·R Zahn, U Zeymer
Dec 12, 2013·Expert Review of Cardiovascular Therapy·Amirreza Solhpour, Syed W Yusuf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.